DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Oculis Holding AG — Static Finviz Chart
Referral applied only on chart click
Nasdaq: $OCS
Ophthalmology
DIAMOND Update
Pipeline Reset
Oculis Holding AG (Nasdaq: $OCS): DIAMOND Phase 3 miss resets the story toward Privosegtor and Licaminlimab
After OCS-01 failed to meet the primary visual acuity endpoint in both DIAMOND Phase 3 trials for diabetic macular edema, Oculis is no longer a clean near-term DME filing story. The new setup is a cash-rich ophthalmology and neuro-ophthalmology pipeline reset, with Privosegtor and Licaminlimab now carrying the next real tests.
Primary endpoint missedBoth DIAMOND trials failed to meet the Week 52 BCVA primary endpoint.
No current FDA filingOculis does not currently plan to pursue an FDA filing for OCS-01 in DME.
$277.6M cashCash, equivalents and short-term investments at March 31, 2026.
2H 2029 runwayThe company says its cash runway extends into the second half of 2029.
New catalyst focus
2026+
From DIAMOND readout to pipeline reset
Oculis has moved past the June 2026 DIAMOND catalyst. The result was not a positive registrational inflection for OCS-01 in diabetic macular edema. The company now needs to rebuild the equity story around Privosegtor in optic neuropathies, Licaminlimab in dry eye disease and disciplined use of a strong cash position.
The next important developments are likely to come from Privosegtor PIONEER execution, future optic neuritis and NAION trial progress, Licaminlimab PREDICT-1 timing around year-end 2026, and any further corporate update on post-DIAMOND resource allocation.
Executive Summary
The Oculis story changed materially on May 29, 2026. Before the DIAMOND readout, OCS was a late-stage ophthalmology catalyst name built around a simple and powerful idea: OCS-01 eye drops could become a non-invasive treatment option for diabetic macular edema. After the readout, that thesis has been deeply reset.
Oculis announced that both Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema failed to meet the primary endpoint of mean change in best corrected visual acuity, measured by ETDRS letter score at Week 52. The key secondary endpoint measuring the proportion of patients with at least a 15-letter BCVA gain was also not met in both studies.
The result was not completely empty from a biological perspective. OCS-01 showed a substantial and persistent reduction in retinal thickness as measured by OCT in DIAMOND-2 at all visits and in DIAMOND-1 at all visits except Week 52. Oculis also reported that OCS-01 was well tolerated and that no unexpected adverse events were observed. But for a DME registrational story, the missing visual endpoint is the problem that matters most.
The most important sentence in the company’s update is not about OCT. It is that, based on the DIAMOND results, Oculis does not currently plan to pursue an FDA regulatory filing for OCS-01 in diabetic macular edema. That changes the equity story from “near-term DME filing candidate” to “pipeline reset after a lead-program disappointment.”
Oculis is not finished. The company still has a strong cash position, a stated runway into the second half of 2029, Privosegtor moving through a registrational neuro-ophthalmology program and Licaminlimab in a genotype-based dry eye disease trial. The stock, however, now needs to be analyzed through a new framework. OCS-01 in DME is no longer the central near-term value driver. Privosegtor and Licaminlimab now carry the burden of rebuilding confidence.
Fast Snapshot
| Item | Updated read |
|---|---|
| Company | Oculis Holding AG |
| Ticker | Nasdaq: OCS |
| Main old catalyst | DIAMOND-1 and DIAMOND-2 Phase 3 topline results for OCS-01 in diabetic macular edema |
| DIAMOND outcome | Both trials missed the Week 52 BCVA primary endpoint |
| Key secondary visual endpoint | The proportion of patients with at least a 15-letter BCVA gain was not met in both trials |
| Anatomical signal | Retinal thickness reduction by OCT was observed, but this did not rescue the registrational visual story |
| FDA filing status in DME | Oculis does not currently plan to pursue an FDA filing for OCS-01 in diabetic macular edema |
| Cash position | $277.6 million in cash, cash equivalents and short-term investments as of March 31, 2026 |
| Runway | Into the second half of 2029, according to company guidance |
| New focus | Privosegtor PIONEER program and Licaminlimab PREDICT-1 |
What actually happened in DIAMOND
The DIAMOND program was the centerpiece of the pre-readout Oculis thesis. It consisted of two global, double-masked, randomized, multicenter Phase 3 trials evaluating OCS-01 eye drops against vehicle in diabetic macular edema. The program enrolled more than 800 patients across 119 sites in the United States and other countries.
The clinical question was straightforward: could a topical high-concentration dexamethasone eye drop produce a meaningful improvement in visual acuity in a posterior-segment retinal disease that is currently treated mainly through invasive intravitreal approaches?
The answer, based on topline Phase 3 data, was not strong enough. Both DIAMOND trials failed to meet the primary endpoint of mean change from baseline in BCVA ETDRS letter score at Week 52. The key secondary endpoint of the proportion of patients with at least a 15-letter gain in BCVA also failed in both studies.
Core reset: the DIAMOND result is not simply “mixed.” It contains an anatomical signal, but the pivotal visual endpoints that mattered for the DME filing story were missed. That is why the company no longer plans, at this time, to pursue an FDA filing for OCS-01 in DME.
That distinction is essential for readers. A Phase 3 biotech update can contain positive secondary signals and still be commercially damaging if the endpoint hierarchy fails. In DME, visual acuity is not a cosmetic metric. It is central to clinical relevance, physician adoption, payer logic and regulatory confidence.
Why OCT improvement did not save the thesis
Oculis did report a meaningful anatomical effect. Retinal thickness measured by OCT improved with OCS-01 compared with vehicle, with the company describing the reduction as substantial and persistent in DIAMOND-2 at all visits and in DIAMOND-1 at all visits except Week 52. This matters scientifically because it suggests the drug had biological activity in the retina.
But the equity market does not price biology in isolation. It prices the probability that biology becomes an approvable, reimbursable and commercially usable product. The problem is that the visual endpoint did not confirm the anatomical story in a way that supports a clean DME regulatory path.
For a retina specialist, an OCT improvement can be relevant. For a regulator and commercial market, however, the central question remains whether the patient sees better in a clinically meaningful and reproducible way. The DIAMOND data did not deliver that answer strongly enough.
This is why the post-readout narrative has to be careful. It would be inaccurate to say OCS-01 showed no activity. It would also be misleading to present the OCT signal as if it keeps the original DME thesis intact. It does not. The data may preserve some residual scientific optionality, but they do not preserve the old near-term FDA filing narrative.
The no-filing statement is the real turning point
The most consequential part of the Oculis update was the company’s statement that it does not currently plan to pursue an FDA regulatory filing for OCS-01 in diabetic macular edema. That single point forces a full reset of the prior article.
Before the data, the clean bull setup was that OCS-01 could produce pivotal evidence, support a potential regulatory submission and move toward commercial preparation. After the data, that path is no longer the active base case.
Investors should therefore avoid analyzing Oculis as if DIAMOND merely delayed the DME program. The company may continue to analyze the dataset, and it may preserve optionality around OCS-01 in some form. But the current public position is clear: no FDA filing for OCS-01 in DME is planned at this time.
Old story
Near-term DME readout could support an FDA filing and validate OCS-01 as a non-invasive retina therapy.
New story
OCS-01 missed visual endpoints and no current FDA DME filing is planned.
New question
Can Privosegtor, Licaminlimab and cash runway rebuild the valuation case?
Cash position: the main stabilizer after the setback
Oculis enters this reset from a stronger financial position than many clinical-stage biotech companies. As of March 31, 2026, the company reported $277.6 million in cash, cash equivalents and short-term investments. Management said this provides runway into the second half of 2029.
That matters because a lead-program disappointment can become much more damaging when a company also faces near-term financing pressure. Oculis does not appear to be in that position. The balance sheet gives the company time to continue Privosegtor, Licaminlimab and other strategic work without immediately depending on a distressed capital raise.
The Q1 2026 net loss was CHF 28.9 million, or $36.8 million. The burn is meaningful, as expected for a late-stage clinical company, but the runway guidance gives Oculis flexibility to refocus after DIAMOND rather than simply defend survival.
Cash is not a cure for failed endpoints. It does not make OCS-01 in DME more approvable. It does, however, change the downside profile. Oculis is now a pipeline-reset story with a long runway, not a low-cash biotech forced into immediate damage-control financing.
Privosegtor now becomes the most important program
Privosegtor, formerly OCS-05, is now the key asset for rebuilding the Oculis story. The program targets optic neuropathies, including acute optic neuritis and non-arteritic anterior ischemic optic neuropathy. This is a difficult field, but it is also an area with significant unmet need and limited treatment options.
The regulatory setup is meaningful. Privosegtor has received FDA Breakthrough Therapy designation and EMA PRIME designation in optic neuritis. Oculis has also announced a Special Protocol Assessment agreement with the FDA for the PIONEER-1 registrational trial, indicating that the design and planned analysis are considered adequate to address the objectives necessary to support a future NDA submission, assuming the trial succeeds and the complete package supports approval.
This does not remove risk. Breakthrough Therapy designation, PRIME designation and SPA agreement are not approvals. They do not guarantee a positive Phase 3 result. But they do matter because they give the program a clearer regulatory framework and signal that regulators see the indication and treatment hypothesis as important enough for enhanced engagement.
In the new OCS framework, Privosegtor is no longer a secondary pipeline asset sitting behind OCS-01. It is the central program to watch. If PIONEER produces strong results, Oculis can rebuild as a differentiated neuro-ophthalmology company. If PIONEER disappoints, the post-DIAMOND story becomes much harder.
Licaminlimab: still alive, still risky
Licaminlimab remains the other meaningful clinical pillar. It is a topical anti-TNFα candidate being developed for dry eye disease through a genotype-based approach. The PREDICT-1 registrational trial is expected to generate topline results around year-end 2026, according to Oculis’ Q1 2026 update.
The strategic appeal is clear: dry eye disease is a large market, and a precision-medicine approach could help identify patients more likely to respond. If the genotype-based strategy works, Licaminlimab could be differentiated from more generalized dry eye therapies.
The risk is also clear. Dry eye has historically been a difficult development area. Symptoms can be subjective, placebo response can be significant, endpoint selection can be challenging and commercial differentiation is not easy. A positive trial would matter, but the market will need more than a marginal statistical win. It will want a convincing patient-selection story, clinically relevant benefit and a believable competitive position.
Updated catalyst calendar
| Date / window | Event | Updated importance |
|---|---|---|
| May 29, 2026 | DIAMOND Phase 3 topline results | Both trials missed the BCVA primary endpoint; no current FDA filing planned for OCS-01 in DME. |
| 2026 | Privosegtor PIONEER program execution | The main rebuilding engine after the DME setback, supported by FDA SPA alignment for PIONEER-1. |
| 2026+ | PIONEER optic neuritis and NAION development | Potential registrational path in optic neuropathies; high unmet need but high clinical risk. |
| Around year-end 2026 | Licaminlimab PREDICT-1 topline results | Important dry eye disease catalyst with a genotype-based precision-medicine angle. |
| Future corporate updates | Resource allocation after DIAMOND | Investors will watch whether spending is disciplined and whether OCS-01 optionality is reduced, paused or reframed. |
For a broader curated biotech-event view, readers can also follow the Merlintrader Free Catalyst Calendar.
Updated bull case
The bull case is no longer built around a clean OCS-01 DME filing path. That part of the story has been reset. The updated bull case is that the market may have punished Oculis for DIAMOND while leaving value in a long-funded pipeline that still includes two serious late-stage opportunities.
Privosegtor is the key. If the PIONEER program confirms a clinically meaningful neuroprotective effect in optic neuritis or NAION, Oculis could become a differentiated neuro-ophthalmology story. The regulatory designations and SPA alignment provide a cleaner development framework than many early clinical stories, even though the clinical risk remains significant.
Licaminlimab adds another possible catalyst around year-end 2026. A strong PREDICT-1 result would help show that Oculis still has productive late-stage development capability after the DIAMOND disappointment.
The final piece is cash. A runway into 2H 2029 gives the company time to execute without immediate survival pressure. In biotech, time is not enough by itself, but time plus real registrational programs can preserve strategic value after a failed catalyst.
Updated bear case and red flags
The bear case is direct: the program that carried the clearest near-term commercial narrative failed the visual endpoints that mattered most. OCS-01 in DME no longer supports the simple “eye drops instead of injections” thesis that made the story easy for the market and retail investors to understand.
The miss also raises broader questions about the OPTIREACH story. OCS-01 showed anatomical activity, but the central commercial question was whether that activity could translate into meaningful visual benefit. DIAMOND did not answer that in the way Oculis needed.
- OCS-01 missed the primary BCVA endpoint in both DIAMOND trials.
- The key secondary endpoint of at least 15-letter BCVA gain was also missed in both trials.
- No current FDA filing for OCS-01 in DME is planned.
- The company now depends more heavily on Privosegtor and Licaminlimab.
- Neuroprotection in optic neuropathies is a difficult development area.
- Dry eye disease is commercially large but clinically and competitively challenging.
- Cash runway is strong, but cash cannot replace clinical validation.
Scenario table after DIAMOND
| Scenario | What it would look like | Market interpretation |
|---|---|---|
| Bull reset | Privosegtor execution strengthens, PIONEER momentum improves, Licaminlimab delivers a credible PREDICT-1 dataset, and cash runway remains disciplined. | Oculis rebuilds from a DME setback into a broader neuro-ophthalmology and dry eye pipeline story. |
| Base reset | OCS-01 DME value is heavily reduced, Privosegtor remains the main asset, Licaminlimab is still pending and the stock trades around cash-adjusted pipeline optionality. | High volatility, but the company remains investable for catalyst-focused traders watching the next data cycle. |
| Bear reset | Privosegtor execution disappoints, Licaminlimab fails or underwhelms, and OCS-01 optionality fades further. | The market increasingly treats Oculis as a cash-backed biotech with delayed or uncertain development value. |
Merlintrader Bottom Line
Oculis is not the same story it was before May 29, 2026. The DIAMOND readout resolved the main near-term catalyst negatively for the OCS-01 DME thesis. The primary BCVA endpoint was missed in both Phase 3 trials, the key secondary visual endpoint was also missed, and Oculis does not currently plan to pursue an FDA filing for OCS-01 in diabetic macular edema.
That does not make the company irrelevant. The cash position is strong, the runway is long, Privosegtor has a serious regulatory framework and Licaminlimab remains a meaningful year-end 2026 catalyst. But the burden of proof has moved. Oculis now has to prove that it is more than the OCS-01 DME disappointment.
The cleanest read is this: the old catalyst thesis has been broken, but the company still has enough capital and pipeline depth to remain on the biotech watchlist. From here, the story is no longer about an imminent DME filing. It is about whether Privosegtor and Licaminlimab can rebuild the market’s confidence after DIAMOND.
Oculis DIAMOND Phase 3 topline results, May 29, 2026 · Oculis Q1 2026 financial results · Oculis FDA SPA agreement for PIONEER-1 · Oculis press releases · Oculis SEC filings · Oculis pipeline
Educational Disclaimer
This content is for informational and educational purposes only and does not constitute investment advice, financial advice, trading advice, a recommendation to buy, sell or hold any security, or personalized guidance. Biotech and clinical-stage companies can be highly volatile, especially around clinical trial readouts, regulatory decisions and financing events. Readers should conduct their own due diligence, review official company filings and consult a qualified financial professional before making investment decisions.
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
